Cooperative Agreement HU00012220067

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $666,609 to North Carolina State University to develop and demonstrate the feasibility of lung quantitative ultrasound (LQUS) for assessing the severity of pulmonary edema due to heart failure and idiopathic pulmonary fibrosis. The goal is to create a real-time, non-invasive, point-of-care method to monitor these lung conditions,...

This federal Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) provides $608,944 to Brigham & Women's Hospital Inc. to develop an AI-assisted strategy for monitoring pulmonary congestion in acute heart failure patients in emergency settings. The project aims to automate lung ultrasound (LUS) congestion scoring using AI/ML...

This $189,332 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Program (CFDA 93.837) aims to transform the delivery of interstitial lung disease (ILD) care through remote patient monitoring and artificial intelligence-powered clinical decision support. The key products and services to be delivered under this 5-year grant include: Identifying provider and health system barriers to adopting a remote patient monitoring...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $269,922 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Steth X Microsystems Inc. to develop a smart, wearable contact microphone patch for extended and remote monitoring of lung functions. The goal is to create a low-profile, battery-powered wireless device capable of accurately detecting and quantifying adventitious lung sounds as well as breathing abnormalities in patients with respiratory...

This three-year, $2.97 million Project Grant from the National Institutes of Health's Trans-NIH Research Support program will support the development of a novel lung research platform to probe pulmonary (patho)physiology in real-time at the cellular level. Trustees of Boston University will receive funding to create the LungEx platform, which includes long-term ex vivo maintenance of mouse and human lungs under near-physiological conditions. A key innovation is a "Crystal" ribcage that...

This Project Grant award of $671,544, funded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop and validate a cardiac ultrasound radiomics-guided deep learning model for precision phenotyping and risk stratification of acute myocardial infarction (AMI) patients. The key products and services to be delivered under this award include: (1) benchmarking the radiomics-guided deep neural network model against conventional...

This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $1,625,000.00 to Onc.ai, Inc. to develop and validate a radiomics-based multi-modal predictive model for metastatic non-small cell lung cancer patients treated with PD-1 immunotherapy. The key objectives are to: 1) Validate the predictive models in a multi-institutional prospective clinical study, 2) Evaluate the performance characteristics and...

The U.S. National Heart, Lung, and Blood Institute (NHLBI) awarded a $802,500 Cooperative Agreement grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Children's Hospital Medical Center in Cincinnati, Ohio. The grant supports the construction of a multi-scale 3D AI-powered map of genetic factors and cellular interactions driving normal and aberrant lung development in childhood interstitial lung disease (CHILD). The project will leverage single-cell and spatial...

This $604,115 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support a longitudinal observational study by The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop non-invasive advanced imaging technologies to predict the development of progressive pulmonary fibrosis in individuals with non-idiopathic pulmonary fibrosis interstitial lung...

This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $144,989.00 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop and test deep generative models using computed tomography (CT) images to predict acute respiratory distress syndrome (ARDS) progression and treatment responses. The project aims to create generative adversarial networks (GANs) that can synthesize CT images...